Virbac: 'strategic' acquisition of Sasaeah in Japan

(CercleFinance.com) - Virbac announces the acquisition of Sasaeah, a major player in the Japanese animal health market.


Virbac says that this strategic acquisition will give the company a leading position in the farm animal vaccine market in Japan, particularly in the cattle segment, and a broad portfolio of pharmaceutical products for all major species.

Formed by the merger of two long-standing players in the animal health sector (Fujita Pharmaceutical Co. Ltd. and Kyoto Biken Laboratories Inc.) under the aegis of ORIX Corporation, Sasaeah generates annual revenues of around E75m, of which around 50% comes from vaccines.

The terms of the deal were not disclosed.


Copyright (c) 2024 CercleFinance.com. All rights reserved.